MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
0.7083
-0.0021
-0.30%
After Hours: 0.6916 -0.0167 -2.36% 19:53 06/14 EDT
OPEN
0.7106
PREV CLOSE
0.7104
HIGH
0.7335
LOW
0.6838
VOLUME
2.10M
TURNOVER
0
52 WEEK HIGH
6.26
52 WEEK LOW
0.5400
MARKET CAP
107.27M
P/E (TTM)
-1.1684
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Intraday Session
Seres Therapeutics stock moved upwards by 34.0% to $0.82 during Monday's regular session. Renovaro (NASDAQ:RENB) shares increased by 32.51%. Champions Oncology stock increased by 22.82%. Novavax stock decreased by 14.62%.
Benzinga · 4d ago
Weekly Report: what happened at MCRB last week (0603-0607)?
Weekly Report · 5d ago
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of GameStop Corp. Fell 22.5% to $36.07 on Friday. The company released worse-than-expected first-quarter results before schedule. Trinity Place Holdings Inc. Shares jumped 165.4% after declining around 11% on Thursday. Leafly Holdings, Inc. And Venus Concept Inc. Also gained in the mid-day session.
Benzinga · 06/07 17:07
Seres Therapeutics Cut to Perform From Outperform by Oppenheimer
Dow Jones · 06/07 16:53
Oppenheimer Downgrades Seres Therapeutics to Perform
Benzinga · 06/07 16:43
12 Health Care Stocks Moving In Friday's Intraday Session
Venus Concept (NASDAQ:VERO) shares rose 87.9% to $1.1 during Friday's regular session. Asensus Surgical (AMEX:ASXC) stock moved upwards by 41.22%. Geron stock rose 21.07% and Biomea Fusion stock declined by 63.1% during the session.
Benzinga · 06/07 16:31
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 06/07 13:00
Seres Therapeutics Price Target Cut to $10.00/Share From $15.00 by Canaccord Genuity
Dow Jones · 06/07 13:00
More
About MCRB
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.